Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 24, Issue 4, Pages 319-333Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2013.01.005
Keywords
Immunogenic cell death; ICD inducers; Cancer; Tumour immunology; Anti-tumour immunity
Categories
Funding
- KU Leuven [GOA/11/009]
- Federal Research Programme [IAP 6/18]
- FWO-Vlaanderen [G.0661.09, G.0728.10, G.0584.12N, G.0728.10 31507110, 3G067512, G060713N, G0A5413N]
- BOF Postdoctoral Mandate (PDM) from KU Leuven [PDMK/12/146]
Ask authors/readers for more resources
Recently, cytokine-based pro-tumourigenic signalling has been found to play a major role in the immune system's pro-tumourigenic activity. On the other hand, other recent findings have shown that immunogenic cancer cell death triggered by certain anticancer modalities might reset the dysfunctional immune system towards the activation of a long-lasting protective anti-tumour response. Therefore, using inducers of immunogenic cell death (ICD) that can prevent or impede tumour-promoting cytokine signalling is one of the best ways of instigating or restoring efficient anti-tumour immunity. In this review it is discussed, how the different ICD inducers interact with the immune system and influence cytokine-based pro-tumourigenic signalling. We believe that it is crucial to discover or develop new anticancer therapeutic modalities that can induce ICD and impede tumour-promoting cytokine signalling. (C) 2013 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available